History of Research on Tumor Angiogenesis

In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that t...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Ribatti, Domenico (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Dordrecht : Springer Netherlands, 2009.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02959nam a22004935i 4500
001 978-1-4020-9563-4
003 DE-He213
005 20151204190945.0
007 cr nn 008mamaa
008 100301s2009 ne | s |||| 0|eng d
020 |a 9781402095634  |9 978-1-4020-9563-4 
024 7 |a 10.1007/978-1-4020-9563-4  |2 doi 
040 |d GrThAP 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 614.5999  |2 23 
100 1 |a Ribatti, Domenico.  |e author. 
245 1 0 |a History of Research on Tumor Angiogenesis  |h [electronic resource] /  |c by Domenico Ribatti. 
264 1 |a Dordrecht :  |b Springer Netherlands,  |c 2009. 
300 |a X, 126 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. 
650 0 |a Medicine. 
650 0 |a History. 
650 0 |a Cancer research. 
650 0 |a Oncology. 
650 0 |a Pathology. 
650 0 |a Cell biology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Cancer Research. 
650 2 4 |a Oncology. 
650 2 4 |a History of Science. 
650 2 4 |a Pathology. 
650 2 4 |a Cell Biology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781402095597 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4020-9563-4  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)